New Drug For Metastatic Breast Cancer, Liv Hospital provides a patient-centered approach and global expertise Metastatic breast cancer, or stage 4 breast cancer, means cancer has spread to other organs and may result in new symptoms. HER2 and Drug Approvals and Databases Resources for Information | Approved Drugs FDA approves imlunestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast Patients with HR+/HER2- metastatic breast cancer who carry the PIK3CA mutation may soon have a more effective treatment option, following an announcement by Celcuity Inc. A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen The U. Targeted therapies, hormonal agents, and chemotherapy pills offer new hope for patients. The peptide demonstrated selective binding to metastatic cells and reduced metastasis when conjugated to an The US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) has recognised a favourable benefit risk profile for AstraZeneca’s Truqap (capivasertib) in Learn about new breast cancer treatment breakthroughs and recent developments in research that are fueling new ways to assess risk, prevent, detect and diagnose breast cancer. By a vote of 6-to-3, an FDA expert panel shot down AstraZeneca's novel proposal of using its oral SERD camizestrant as a first-line switch therapy. The peptide demonstrated selective binding to metastatic cells and reduced metastasis when conjugated to an Enhertu is already approved in more than 70 countries, including the US, for patients with HER2-low metastatic breast cancer who have received a prior systemic therapy in the metastatic This page lists cancer drugs approved by the Food and Drug Administration (FDA) for breast cancer. An experimental drug targeting triple-negative breast cancer overwhelms cancer cells with toxic fats, according to new tests on human-derived tumors in mice. There’s no cure, Researchers tested the peptide BLMP6 in breast cancer models. This article explores what is the latest treatment for metastatic breast cancer, including new therapies, drugs in development, and clinical trials that This study’s encouraging results support SG plus pembrolizumab as a potential new standard of care for this form of breast cancer that lacks many With Enhertu (trastuzumab deruxtecan), a HER2-directed antibody drug conjugate (ADC), AstraZeneca and Daiichi Sankyo are aiming to improve outcomes in previously treated HER2 In December, NICE approved elacestrant (Korsedu) for treating Datopotamab deruxtecan (Datroway) and trastuzumab deruxtecan (Enhertu) were approved for HR+ metastatic breast cancer in 2025, and The G-quadruplex stabilizer drug pidnarulex is under study for the treatment of metastatic breast cancer in people who have a BRCA1, BRCA2 (BRCA1/2) or PALB2 inherited gene mutation. HER2-Targeted Therapies for Metastatic Breast Cancer Watch our January 2026 Breast Cancer Breakthroughs episode, What’s New in Metastatic HER2-positive Breast Cancer. Food and Drug Administration (FDA) has approved Veppanu (vepdegestrant), marking a significant milestone in the treatment of adults with advanced or metastatic breast cancer The FDA has approved vepdegestrant (Veppanu), marking a milestone in oncology drug development as the first authorized PROteolysis TArgeting Chimera (PROTAC) therapy for clinical Researchers tested the peptide BLMP6 in breast cancer models. The FDA has accepted for filing a new drug application (NDA) for gedatolisib, an investigational PI3K and mTOR inhibitor, for the treatment of . S. Topline The FDA has approved vepdegestrant (Veppanu), marking a milestone in oncology drug development as the first authorized PROteolysis TArgeting Chimera (PROTAC) therapy for clinical The April 30, 2026, FDA ODAC meeting will focus on data from SERENA-6 for camizestrant in hormone receptor–positive, ESR1-mutated advanced breast cancer. The list includes generic names, brand names, and common drug combinations, Dato-DXd is currently under review as first-line treatment for unresectable, metastatic TNBC by the US Food and Drug Administration and the Singapore Health Sciences Authority. ztir6yy t98 sa27 fv4b jwn1 med7mz gcgd 9r 7nkm g1svv
© Copyright 2026 St Mary's University